Health

Health stocks gain momentum in early January 2026 trading, buoyed by positive vaccine developments and analyst outlooks highlighting resilient demand...

The World Health Organization (WHO) highlights significant global disease control milestones in 2025, demonstrating major progress in eliminating and reducing...

The Trump administration secures groundbreaking drug pricing agreements with major pharmaceutical companies, aiming to significantly lower costs for Medicaid beneficiaries...

Kyoto University Hospital's September 2025 launch of the world's first human trial for tooth-regrowth drug TRG035—targeting USAG-1 inhibition—ushers regenerative dentistry's...

The FDA's December 2025 approval of deuruxolitinib (Leqselvi®) as a first-line oral therapy for moderate-to-severe alopecia areata (AA) in adults...

The quest for anti-aging elixirs pivots to immunology's vanguard: CAR T-cell therapies, once cancer's scourge, now target senescence—the cellular "zombie"...

Stanford's PRIMAvera trial in October 2025 heralds vision's return for 5 million GA-AMD sufferers, with photovoltaic retinal implants—2x2mm, 30µm thick—enabling...

Eli Lilly's orforglipron has redefined obesity therapeutics, achieving up to 28% average body weight loss in pivotal Phase 3 ATTAIN-1...

Treatment-resistant depression (TRD), afflicting 30% of 21 million U.S. MDD cases, gains a standalone warrior: FDA's January 21, 2025, approval...

Lung cancer, claiming 1.8 million lives yearly, witnesses vaccine revolutions: mRNA platforms repurpose COVID-19 tech for neoantigen targeting, while LungVax...